How to dance with porcupines: rules and guidelines on doctors’ relations with drug companies

Elizabeth Wager

Interactions between doctors and drug companies can lead to ethical dilemmas. This article gives an overview of the guidance and codes of practice that aim to regulate the relationship.

Drug company codes of practice

Codes of conduct for pharmaceutical companies developed by industry organisations tend to be voluntary but are often backed up by complaints procedures. Many countries with major pharmaceutical sectors have national codes, such as those of the Association of British Pharmaceutical Industry (ABPI), Medicines Australia, and the Pharmaceutical Research and Manufacturers of America. These usually concentrate on drug companies’ marketing activities—most prohibit companies from giving doctors inducements to prescribe their products in the form of payments, lavish gifts, or extravagant hospitality.

The ABPI code stipulates that gifts from companies must cost less than £5 (about $9 or €10) and be relevant to the doctor’s work. The accompanying guidance helpfully explains that pens, diaries, and surgical gloves “have been held to be acceptable,” whereas table mats, plant seeds, and music CDs are not. The level of hospitality for meetings must be “appropriate and not out of proportion to the occasion,” and costs “must not exceed that level which the recipients would normally adopt when paying for themselves.” The Australian guidelines state that hospitality should be “simple, modest [and] secondary to the educational content” of a meeting. The venue for such meetings “must not be chosen for its leisure and recreational facilities,” and travel for journeys of under four hours “should be economy class.” In the United States, guidelines on gifts to physicians were strengthened in 2002. As in the United Kingdom, pens and calendars are permissible, but golf balls and DVD players are not.

For countries without national codes, two sets of international guidelines apply. These are the World Health Organization’s Criteria for Medicinal Drug Promotion and the Code of Pharmaceutical Marketing Practice from the International Federation of Pharmaceutical Manufacturers Associations. Like the national guidelines, these codes cover promotional materials, which must, according to WHO, be “relatable,
accurate, truthful, informative, balanced, up-to-date, capable of substantiation and in good taste.” The WHO guidelines also cover the activities of representatives and the supply of drug samples.

In France, doctors’ relations with commercial companies are covered by the legal Code de la Sante Publique (article L.4113-6). This prohibits doctors from receiving benefits worth more than about €30 (£22; $34). Infringement of article 24 of the “code de déontologie” of the Conseil National de l’Ordre des Médecins, which relates to illegal payments to doctors, carries a fine of up to €75 000 (£55 000; $84 000) and a two year prison sentence.

In the United Kingdom, self policing of the ABPI Code of Practice seems to work quite well, judging by the proportion of complaints submitted by competitor companies. Complaints are reviewed by the Prescription Medicines Code of Practice Authority, which acts independently of the ABPI and comprises 12 members from pharmaceutical companies, six independent members, and a legally qualified chairman. Results are published in the Code of Practice Review.

Unlike many other industry organisations, the ABPI also offers guidance on research. It has developed a model clinical trial agreement for industry sponsored research in the NHS and guidance notes for NHS R&D managers. However, in many other countries industry guidelines relate solely to promotional activities.

Guidance from other organisations

In contrast, many doctors’ organisations offer guidance about commercially funded research. The Association of American Medical Colleges has issued two documents entitled Protecting subjects, preserving trust, promoting progress, one aimed at academic institutions and the other at individual clinicians. These were developed in response to “deepening public concern over researchers’ perceived conflicts of interest,” and they aim to set out principles “for the oversight of financial interests in research involving human subjects.”

The American College of Physicians has its own guidelines, first issued in 1990 and extended in 2002, which cover both marketing and research collaboration. Like the Association of American Medical Colleges, the college offers guidance to both individuals and institutions, including medical societies and institutions involved in medical education. The 1990 American College of Physicians guidelines state that “a useful criterion in determining acceptable activities and relationships is: Would you be willing to have these arrangements generally known?”

The International Committee of Medical Journal Editors strengthened its requirements on declaring conflicts of interest in 2001. Since 1999 the US Food and Drug Administration has required companies to supply information about investigators’ financial interests when submitting a licensing application.

Academic institutions have been slow to provide helpful policies on conflict of interest to assist investigators. Cho and colleagues surveyed 100 US institutions and concluded that most policies “lack specificity about the kinds of relationships with industry that are permitted or prohibited” and that such ambiguous policies were likely to cause “unnecessary confusion.”

Academic institutions have also been criticised for their failure to prevent employees from signing restrictive contracts with companies and their failure to support employees when industrial sponsors threaten legal action to enforce such agreements. Journal editors, concerned by some well publicised cases of companies attempting to veto publications and suppress unfavourable findings, have tried to strengthen the position of investigators by encouraging greater transparency. In September 2001 several members of the International Committee of Medical Journal Editors issued a statement entitled Sponsorship, Authorship, and Accountability. Although the aim of protecting doctors against unethical and restrictive contracts is laudable, I believe that some of the proposed solutions go too far (and they have also been criticised by others). In particular, the demand for “independent” analysis of trials disregards the considerable statistical expertise to be found within the industry. The statement also seems confused about the role of contract research organisations in developing protocols. Not all members of the international committee endorsed the statement, and the BMJ published its own, more measured, editorial. Despite my reservations, many parts of the statement are helpful, and the greater transparency about company involvement may increase understanding of the complex collaboration that often occurs during trials and also discourage unacceptable practices.

Some organisations for doctors who work directly for pharmaceutical companies (perhaps we could call them professional porcupine dancers) have also produced guidelines. The American Academy of Pharmaceutical Physicians has a Code of Ethics, but it is brief and rather general. However, the ethics subcommittee of the Royal College of Physicians Faculty of Pharmaceutical Medicine has issued helpful and detailed guidance on “ethics and pharmaceutical medicine,” which also contains a useful list of other relevant guidelines.

Most guidelines and regulations reviewed so far cover interactions that arise as a result of marketing or clinical trials. Although journal editors have published their views about company involvement in studies, until very recently no specific guidelines existed to encourage responsible practice for producing publica-
tions from trials sponsored by drug companies. However, guidelines on Good Publication Practice for Pharmaceutical Companies have recently been published.16 These encourage companies to publish the results of all clinical trials of licensed products, set out measures designed to prevent publication bias, and, uniquely, address the role of professional medical writers employed by companies to work with doctors to develop publications. The Committee on Publication Ethics has also published guidelines on good publication practice, but these are more general and are designed to assist editors and authors.27

The Office of the Inspector General of the US Department of Health and Human Services has issued guidance to American pharmaceutical manufacturers for developing guidelines to ensure that they comply with all the relevant legislation.19 Companies' interactions with doctors may also be influenced by international regulations governing clinical research and local measures to prevent research misconduct.

Conclusions
What can we conclude about regulations designed to choreograph the porcupine dance? Most were developed only recently, and many are still evolving. They come from many organisations with different aims and are therefore scattered and occasionally conflicting, although consensus seems to exist on the broad principles. From my own experience of more than a decade of working closely with the industry and with doctors, misapprehensions and misunderstandings persist on both sides. I would therefore urge proper dialogue between the parties before any more guidelines or regulations are drawn up or revised. Guidelines developed jointly by doctors working both inside and outside the industry might be more widely accepted than those from a single constituency.

Drug companies, like porcupines, come in a range of shapes and sizes; some are fiercer than others, and this diversification must be recognised. The relationships between doctors, academic institutions, pharmaceutical companies, and medical journals will always be complex and interdependent, but we should not forget that the dance has produced some remarkable collaborations that have enabled the discovery and development of the medicines we all rely on.

Competing interests: EW has been an employee of Janssen-Cilag and GlaxoWellcome. She is now self employed but still works mainly for pharmaceutical companies. She has done one project for the ABPI and also advised on its publication policy. She is a member of the working group that has produced Good Publication Practice for Pharmaceutical Companies and is involved in promoting these guidelines.

References
2 Committee on Publication Ethics: www.publicationethics.org
3 Good Publication Practice for Pharmaceutical Companies: www.gpp-guidelines.org
4 International Committee of Medical Journal Editors: www.icmje.org
10 Reenie D. Thyroid storms. JAMA 1997;277:1238-43.
11 Korenman SG. The role of journal editors in the responsible conduct of industry-sponsored biomedical research and publication: a view from the other side of the editor’s desk. Science Editor 2003;26:42-3.